NCT05629442
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
StatusWithdrawn
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Withdrawn before enrolling Sponsor's reason: Funding issues Show 4 more changesShow less
- Enrollment target: estimated 60 to confirmed 0
- Eligibility criteria expanded, about 10 words
- Study sites: 2 to 0
- Secondary endpoints: details revised at 8 of 10 entries
- Minor Site details revised at 1 of 2 sitesv3
- Notable Primary completion date: Jun 2026 to Jun 2028
- Start date: Jan 2023 to Oct 1, 2026
- Site contacts updated at 2 of 2 sites
- Collaborators: 2 to 1
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Rate of successful non-operative management
Timeframe: 1 year
Rate of successful pathologic complete response
Timeframe: 1 year
Secondary (10)
Rate of local recurrence
EORTC-QLQ-CR 29 questionnaire
FACT-C questionnaire
IADL Scale
Brief Pain Inventory (BPI) questionnaire
Show 5 moreShow less
Bowel function assessment with LARS score
Bowel function assessment with FISI score
Bowel function assessment with FIQOL score
Disease-free survival (DFS)
Overall Survival (OS)
Arms and interventions
EVALUATION OF CTDNA
This prospective observational, non-therapeutic study will enroll patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy/ All procedures involved with this trial will be done as per standard of care \- Except for the initial research biopsy, quality of life assessments and ctDNA collection
Other: ctDNA